# Sonder Capital

> Sonder Capital is a VC fund backing Health Care and Medical Device. See 21 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Redwood City, United States
- Total investments: 21
- Last investment: Apr 2026
- Lead investor: 81%
- Last updated: Aug 2026
- Website: https://www.sondercapital.com/

Sonder Capital is a VC fund in Redwood City focused on Health Care and Medical Device. Sonder Capital invests in teams and technologies that can transform healthcare in the medical device, diagnostic and healthtech sectors. We are Foundational Investors – we commit our energy and capital early to guide and support companies from inception to acquisition or IPO. We look for big ideas that will change lives.

## Contacts

5 contacts available for Sonder Capital. Shizune tracks 5 team members at Sonder Capital. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/sonder-capital?utm_source=investor_profile

## Round sizes

| Stage | Round size |
| --- | --- |
| Seed | $8M–$18M |
| Series A | $13M–$22M |
| Series B | $20M–$70M |

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 7 | 33% |
| Medical Device | 5 | 24% |
| Medical | 3 | 14% |
| Biotechnology | 2 | 10% |
| Manufacturing | 2 | 10% |

12 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 5 | 24% |
| Seed | 2 | 10% |
| Series B | 1 | 5% |
| Series C | 1 | 5% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 5 | 24% |
| France | 1 | 5% |
| United Kingdom | 1 | 5% |
| The Netherlands | 1 | 5% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Andy McGibbon | Managing Partner | 4 | https://shizune.co/investors/profile/andy-mcgibbon |
| Colby Wood | Managing Partner | 0 | https://shizune.co/investors/profile/colby-wood |
| Jay Watkins | Managing Partner | 13 | https://shizune.co/investors/profile/jay-watkins |
| Fred Moll, M.D | Managing Partner | 28 | https://shizune.co/investors/profile/fred-mole |
| Kate Garrett | Managing Partner | 3 | https://shizune.co/investors/profile/kate-garrett |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| SquareMind | Come build the future of healthcare with us. | $18M | Seed | Apr 28, 2026 |  |
| SquareMind | Come build the future of healthcare with us. | $18M | Seed | Apr 28, 2026 |  |
| Vitestro | Vitestro transform patient care with autonomous blood drawing technology. | $70M | Series B | Mar 10, 2026 |  |
| Vitestro | Vitestro transform patient care with autonomous blood drawing technology. | $70M | Series B | Mar 10, 2026 |  |
| Cordance Medical | Cordance Medical is a medical device company that develops radical therapy for a variety of CNS pathology, including primary and metastatic cancer, Alzheimer's, and Parkinson's diseases. | $8M | Seed | Nov 24, 2025 |  |
| Jupiter Endovascular | Jupiter Endovascular is a medical technology startup developing the endoportal procedure, a new class of endovascular procedures using Endoportal Control to bring the precision and control of direct surgical access to catheter-based interventions. The procedure uses an endoportal device that navigates flexibly through the vasculature viapercutaneous access. Once in position, the endoportal device can be fixed into a stable state to deliver an interventional treatment with surgical-like precision and control from an endovascular access point. |  | Series B | Oct 07, 2025 |  |
| Jupiter Endovascular | Jupiter Endovascular is a medical technology startup developing the endoportal procedure, a new class of endovascular procedures using Endoportal Control to bring the precision and control of direct surgical access to catheter-based interventions. The procedure uses an endoportal device that navigates flexibly through the vasculature viapercutaneous access. Once in position, the endoportal device can be fixed into a stable state to deliver an interventional treatment with surgical-like precision and control from an endovascular access point. |  | Series B | Oct 07, 2025 |  |
| Jupiter Endovascular | Jupiter Endovascular is a medical technology startup developing the endoportal procedure, a new class of endovascular procedures using Endoportal Control to bring the precision and control of direct surgical access to catheter-based interventions. The procedure uses an endoportal device that navigates flexibly through the vasculature viapercutaneous access. Once in position, the endoportal device can be fixed into a stable state to deliver an interventional treatment with surgical-like precision and control from an endovascular access point. |  | Series B | Oct 07, 2025 |  |
| BRIUS | BRIUS is a healthcare company that focuses in the orthodontics and medical device industry. | $19.5M | Series B | May 06, 2025 |  |
| Jupiter Endovascular | Jupiter Endovascular is a medical technology startup developing the endoportal procedure, a new class of endovascular procedures using Endoportal Control to bring the precision and control of direct surgical access to catheter-based interventions. The procedure uses an endoportal device that navigates flexibly through the vasculature viapercutaneous access. Once in position, the endoportal device can be fixed into a stable state to deliver an interventional treatment with surgical-like precision and control from an endovascular access point. | $21M | Series A | Aug 15, 2024 |  |

10 of 21 investments shown.

## Co-investors
- [GT Healthcare Capital Partners](https://shizune.co/investors/profile/gt-healthcare-capital-partners) — VC Fund, 3 deals together
- [LB Investment](https://shizune.co/investors/profile/lb-investment) — VC Fund, 3 deals together
- [NYBC Ventures](https://shizune.co/investors/profile/nybc-ventures) — VC Fund, 3 deals together
- [Senvest Management](https://shizune.co/investors/profile/rima-management) — VC Fund, 3 deals together
- [Adamed Pharma](https://shizune.co/investors/profile/adamed-pharma) — VC Fund, 2 deals together
- [Addington Investment Group](https://shizune.co/investors/profile/addington-investment-group) — VC Fund, 2 deals together

## Similar investors

### Similar industry
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [SV Angel](https://shizune.co/investors/profile/sv-angel) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

### Similar country
- [SFC Capital](https://shizune.co/investors/profile/startup-funding-club) — VC Fund
- [Fuel Ventures](https://shizune.co/investors/profile/fuel-ventures-fund) — VC Fund
- [Business Growth Fund](https://shizune.co/investors/profile/business-growth-fund) — VC Fund

## Featured in investor lists
- [Social Network VC Funds in United Kingdom](https://shizune.co/investors/social-network-vc-funds-united-kingdom)

## FAQ

### What does Sonder Capital invest in?

Sonder Capital invests primarily in Health Care, Medical Device and Medical startups, most often at Series A and Seed stage. Most of the 21 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### What is Sonder Capital's check size?

Sonder Capital typically joins rounds of $8M–$18M at Seed, $13M–$22M at Series A and $20M–$70M at Series B. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Sonder Capital participates in.

### How do I contact Sonder Capital?

Public channels for Sonder Capital include the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Sonder Capital?

The team at Sonder Capital includes Andy McGibbon (Managing Partner), Colby Wood (Managing Partner) and Jay Watkins (Managing Partner). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co